Imatinib Mesylate Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 50 mg, 100 mg, 400 mg
Reference Brands: Gleevec® (EU & US)
Category:
Oncology Cancer Care
Imatinib Mesylate is available in oral tablet form, with common strengths of 100 mg, 400 mg, and 50 mg. The drug is sold under the brand Gleevec® (by Novartis) and also in generic versions from manufacturers like Teva, Sandoz, and Mylan. It is widely used in the US and EU for treating cancers such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).
Imatinib Mesylate is available in Tablet
and strengths such as 50 mg, 100 mg, 400 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Imatinib Mesylate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Imatinib Mesylate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Imatinib Mesylate is a targeted therapy used in oncology to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and other cancers. Available under the brand Gleevec® by Novartis and as generics, Imatinib is an essential tyrosine kinase inhibitor (TKI) used in cancer centers, hospitals, and oncology clinics. It blocks the action of abnormal proteins that contribute to cancer cell growth, making it crucial for effective cancer management. Available in oral tablets and generics, Imatinib Mesylate is widely sourced by B2B pharmaceutical wholesalers in the US and EU, ensuring reliable supply and GMP-compliant distribution for cancer treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing